Effects of statins on the epicardial fat thickness in patients with coronary artery stenosis underwent percutaneous coronary intervention: comparison of atorvastatin with simvastatin/ezetimibe.
BACKGROUND
Epicardial fat is a visceral thoracic fat and known to be related with presence of dyslipidemia and coronary arterial stenosis. We evaluated the effects and differences of statins on epicardial fat thickness (EFT) in patients underwent successful percutaneous coronary intervention (PCI).


METHODS
In this retrospective cohort study, we enrolled consecutive patients underwent successful PCI and scheduled six to eight-months follow-up coronary angiography from March 2007 to June 2009. EFT was measured by echocardiography twice at the time of PCI and the follow-up coronary angiography. We included 145 patients (58 females; mean, 63.5 ± 9.5 years).


RESULTS
Of the 145 patients, 82 received 20 mg of atorvastatin (atorvastatin group) and 63 medicated with 10 mg of simvastatin with 10 mg of ezetimibe (simvastatin/ezetimibe group). With statin treatments, total cholesterol concentration (189.1 ± 36.1 to 143.3 ± 36.5 mg/dL, p < 0.001), triglycerides (143.5 ± 65.5 to 124.9 ± 63.1 mg/dL, p = 0.005), low density lipoprotein-cholesterol (117.4 ± 32.5 to 76.8 ± 30.9 mg/dL, p < 0.001) and EFT (4.08 ± 1.37 to 3.76 ± 1.29 mm, p < 0.001) were significantly decreased. Atorvastatin and simvastatin/ezetimibe showed similar improvements in the cholesterol profiles. However, atorvastatin decreased EFT more significantly than simvastatin/ezetimibe (EFT change 0.47 ± 0.65 in the atorvastatin vs. 0.12 ± 0.52 mm in the simvastatin/ezetimibe group; p = 0.001).


CONCLUSIONS
In this study, the atorvastatin group showed significant reduction in EFT than in the simvastatin/ezetimibe group. This might be originated from the statin difference. More large, randomized study will be needed to evaluate this statin difference.
Division of Cardiology, Department of Internal Medicine, School of Medicine, Chungnam National University, Chungnam National University Hospital, Daejeon, Korea.
Jae-Hyeong
JH
Park
Yun Seon
YS
Park
Yeon Ju
YJ
Kim
In Sook
IS
Lee
Jun Hyung
JH
Kim
Jae-Hwan
JH
Lee
Si Wan
SW
Choi
Jin-Ok
JO
Jeong
In-Whan
IW
Seong
Lancet. 1986 Feb 8;1(8476):307-10
2868172
N Engl J Med. 2008 Apr 3;358(14):1431-43
18376000
Diabetes Care. 2007 Sep;30(9):2392-4
17563343
Am Heart J. 2007 Jun;153(6):907-17
17540190
Obesity (Silver Spring). 2006 Oct;14(10):1679-84
17062795
Curr Pharm Des. 2007;13(21):2180-4
17627550
Circ J. 2007 Apr;71(4):536-9
17384455
Dev Biol. 1978 Oct;66(2):579-85
700255
J Clin Endocrinol Metab. 2003 Nov;88(11):5163-8
14602744
JAMA. 2002 Dec 4;288(21):2709-16
12460094
Circulation. 2002 Jun 18;105(24):2923-8
12070124
Ann Intern Med. 2006 Oct 3;145(7):554-5; author reply 555
17015879
Int J Obes. 1990 Dec;14(12):1013-22
2086494
Pharmacol Rep. 2009 Nov-Dec;61(6):1134-45
20081249
J Am Coll Cardiol. 2005 Oct 18;46(8):1425-33
16226165
Comp Biochem Physiol B. 1989;94(2):225-32
2591189
Int J Obes Relat Metab Disord. 2000 Jan;24(1):60-9
10702752
Lancet. 2001 Feb 24;357(9256):577-81
11558482
Nat Clin Pract Cardiovasc Med. 2005 Oct;2(10):536-43
16186852
Am J Cardiol. 2007 May 15;99(10):1470-2
17493483
Cardiovasc Diabetol. 2006 Jan 13;5:1
16412224
Atherosclerosis. 2001 Jul;157(1):203-9
11427222
Obes Res. 2003 Feb;11(2):304-10
12582228
Heart. 2008 Mar;94(3):e7
17923467
Obesity (Silver Spring). 2008 Jul;16(7):1693-7
18451775
N Engl J Med. 2008 Oct 2;359(14):1426-7
18832243